10-K: Medicale Corp. Reports Full Year 2024 Results, Cites Going Concern Uncertainty

Medicale Corp.'s 2024 annual report reveals a net loss of $58,213 and ongoing concerns about the company's ability to continue as a going concern.

Summary

• Medicale Corp., a development stage company, reported a net loss of $58,213 for the fiscal year ended September 30, 2024, compared to a net loss of $37,138 in the previous year.
• The company has not generated any revenue from its business operations during the fiscal years 2024 and 2023.
• Operating expenses increased to $54,707 in 2024 from $37,593 in 2023 due to increased operational activities.
• The company's total assets remained at $159 as of September 30, 2024 and 2023.
• Net cash used in operating activities was $83,585 in 2024, compared to $25,739 in 2023.
• The company financed its operations primarily through advances from third-party investors and the issuance of equity, with net cash provided by financing activities of $83,585 in 2024.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and lack of revenue generation.
• The company has a material weakness in internal control over financial reporting due to lack of segregation of duties, a limited corporate governance structure, and a lack of a formal management review process.
• As of January 13, 2025, the company had 5,920,000 shares of common stock outstanding.

Sentiment

Score: 2

Explanation: The document paints a very negative picture due to the lack of revenue, increasing losses, going concern opinion, and material weakness in internal controls. The company's future is highly uncertain.

Positives

• The company has secured $83,585 in financing activities during the fiscal year 2024.
• The company is actively attempting to raise capital and continue public reporting.

Negatives

• The company has not generated any revenue from its business operations.
• The company experienced a net loss of $58,213 for the fiscal year ended September 30, 2024.
• Operating expenses increased significantly to $54,707 in 2024.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• There is a material weakness in internal control over financial reporting.
• The company has an accumulated deficit of $175,845 as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and lack of revenue.
• The company has limited capital resources and may face cost overruns.
• The company's internal control over financial reporting has a material weakness.
• The company may not be able to raise sufficient capital to fund its operations.
• Equity financing could result in additional dilution to existing shareholders.
• The COVID-19 pandemic could have a material adverse impact on the company's future operating results.

Future Outlook

The company anticipates being dependent on additional investment capital to fund operating expenses and intends to raise funds through the capital markets, but there are no assurances of success.

Management Comments

• Management believes that the company will be dependent on additional investment capital to fund operating expenses.
• Management intends to position the company to raise additional funds through the capital markets.
• Management acknowledges the material weakness in internal control over financial reporting and plans to monitor and assess the costs and benefits of additional staffing to remediate it.

Industry Context

As a development stage company in the dietary supplement and consulting services sector, Medicale Corp. faces significant challenges in establishing a revenue stream and achieving profitability. The company's financial situation is not uncommon for early-stage businesses, but the going concern opinion from auditors highlights the severity of the challenges.

Comparison to Industry Standards

• Many development stage companies in the biotech and healthcare sectors experience similar challenges with revenue generation and profitability in their early years.
• Companies like 'Xometry' and 'Shapeways' in the manufacturing sector, which also started with limited operations, faced similar going concern issues in their early stages.
• The lack of revenue and the significant net loss are not uncommon for companies in the early stages of development, but the material weakness in internal controls is a significant concern.
• The company's reliance on convertible notes for financing is a common practice for early-stage companies, but the high interest rate of 8% may be a burden in the long term.
• Compared to established companies in the dietary supplement industry, Medicale Corp. is significantly behind in terms of revenue, profitability, and operational scale.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings, and is not aware of any pending or potential legal actions.

Related Party Transactions

• The previous majority shareholder, Borisi Alborovi, forgave debt of $51,192 owed to him by the company.
• The company's sole officer and director, Chen Zu De, provides the company's office space on a rent-free basis.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees are at risk due to the company's financial instability and potential inability to continue operations.
• Creditors face risk due to the company's financial instability and potential inability to repay debts.
• The company's suppliers may be impacted by the company's financial instability and potential inability to pay for goods and services.

Next Steps

• The company intends to raise additional funds through the capital markets.
• The company plans to monitor and assess the costs and benefits of additional staffing to remediate the material weakness in internal control over financial reporting.
• The company plans to bring its tax filings current as soon as is practical.

Key Dates

Keywords

financial statements, going concern, net loss, internal control, operating expenses, capital raise, development stage, convertible note, material weakness, auditor opinion